Diabetes Drugs SGLT2i and GLP-1 RAs may Reduce Risk of Pneumonia and Sepsis, finds research Dr Riya Dave19 Dec 2024 8:15 AM ISTResearchers have discovered that sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), often...
SGLT2 inhibitors significantly reduce inflammatory markers like IL-6 alongside blood sugar control Medha Baranwal1 Dec 2023 10:00 AM ISTIran: A recent meta-analysis and systematic review reveals significantly reduced levels of the pro-inflammatory biomarker interleukin-6 (IL-6) with...
Canagliflozin has no effect on SBP variability and associated CV and renal complications: JAHA Medha Baranwal27 Jun 2023 10:00 AM ISTAustralia: Analysis of participants' data from the CANVAS and CREDENCE Trials revealed that canagliflozin (an SGLT2 inhibitor) has little or no effect...
